Opus Genetics, Inc. (NASDAQ: IRD) is a Healthcare company (Biotechnology) with a market capitalization of $338M. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Opus Genetics, Inc. had a Maz Rating of 3.55 out of 5 (B+, Buy), ranked against the other companies in its sector. Its strongest factor then was Momentum (4.36), above most of its sector; its weakest was Profitability (1.39), among the weakest in its sector. The other factors: Financial Health 3.50 (above most of its sector); Growth 2.91 (around the middle of its sector); Valuation 2.83 (valued in line with its sector). The current rating is for members: log in to see it.
At $4.06, Opus Genetics, Inc. trades at 42.6x sales and 10.7x book value. Over the last twelve months it generated about $8M of revenue and a net loss of $127M. It runs a gross margin of 99.8%, an operating margin of -777.7% and a net margin of -1726.7%. It shows return on equity of 10838.9%, return on invested capital of -72.0% and a free cash flow yield of -14.4%. On the balance sheet: a debt-to-equity ratio of 0.90 and a current ratio of 9.65. Over the past 52 weeks the share price ranged from $1.70 to $7.07, with a beta of 0.62.
Opus Genetics, Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 9 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.